Overview

Financials

News Discussions Technicals Forecast Seasonals Options

ANAB fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

‪563.04 M‬USD

—

−5.20USD

2005

136

Daniel R. Faga

anaptysbio.com

About

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Ownership

‪‪30.67 M‬‬

Free Float shares

‪‪28.29 M‬‬ (92.24%)

Closely held shares

‪‪2.38 M‬‬ (7.76%)

Free Float shares

‪‪28.29 M‬‬ (92.24%)

Closely held shares

‪‪2.38 M‬‬ (7.76%)

Capital structure

Market cap

‪‪563.04 M‬‬

Debt

‪‪369.46 M‬‬

Cash & equivalents

‪‪385.37 M‬‬

Enterprise value

‪‪547.13 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary

‪‪563.04 M‬‬

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

6.32x

Market Cap

Net income

Revenue

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

6.32x

Valuation ratios

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪0.00‬

‪9.00‬

‪18.00‬

‪27.00‬

‪36.00‬

P/S

Growth and Profitability

Company’s recent performance and margins

Performance

‪−650%‬

‪−500%‬

‪−350%‬

‪−200%‬

‪−50%‬

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−50.00 M‬‬

‪‪−25.00 M‬‬

‪0.00‬

‪‪25.00 M‬‬

‪‪50.00 M‬‬

Revenue

Net income

Net margin %

Revenue to profit conversion

Revenue

COGS

Gross profit

Op expenses

Op income

Non-Op income/ expenses

Taxes & Other

Net income

‪‪−50.00 M‬‬

‪‪−25.00 M‬‬

‪0.00‬

‪‪25.00 M‬‬

‪‪50.00 M‬‬

Revenue

COGS

Gross profit

Expenses & adjustments

Net income

‪‪−50.00 M‬‬

‪‪−25.00 M‬‬

‪0.00‬

‪‪25.00 M‬‬

‪‪50.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business

Period: 2024

GSK - Royalty - Jemperli

GSK -Milestones

GSK - Royalty - Zejula

By country

Period: 2024

United States and Australia

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪0.00‬

‪‪11.00 M‬‬

‪‪22.00 M‬‬

‪‪33.00 M‬‬

‪‪44.00 M‬‬

Actual

Estimate

Earnings

Next:May 8, 2025

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪−2.00‬

‪−1.50‬

‪−1.00‬

‪−0.50‬

‪0.00‬

Actual

Estimate

Dividends

Dividend yield, history and sustainability

ANAB does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−130.00 M‬‬

‪0.00‬

‪‪130.00 M‬‬

‪‪260.00 M‬‬

‪‪390.00 M‬‬

Debt

Free cash flow

Cash & equivalents

Financial position analysis

Short term

Long term

‪0.00‬

‪‪110.00 M‬‬

‪‪220.00 M‬‬

‪‪330.00 M‬‬

‪‪440.00 M‬‬

Assets

Liabilities